Paul J Hensbergen, Loes van Huijkelom, Jordy van Angeren, Arnoud H de Ru, Bart Claushuis, Peter A van Veelen, Wiep Klaas Smits, Jeroen Corver
{"title":"Elucidation of the Glycan Structure of the b-type Flagellin of <i>Pseudomonas aeruginosa</i> PAO1.","authors":"Paul J Hensbergen, Loes van Huijkelom, Jordy van Angeren, Arnoud H de Ru, Bart Claushuis, Peter A van Veelen, Wiep Klaas Smits, Jeroen Corver","doi":"10.1021/acsinfecdis.4c00896","DOIUrl":null,"url":null,"abstract":"<p><p>Flagella are essential for motility and pathogenicity in many bacteria. The main component of the flagellar filament, flagellin (FliC), often undergoes post-translational modifications, with glycosylation being a common occurrence. In <i>Pseudomonas aeruginosa</i> PAO1, the b-type flagellin is <i>O</i>-glycosylated with a structure that includes a deoxyhexose, a phospho-group, and a previous unknown moiety. This structure resembles the well-characterized glycan (Type A) in <i>Clostridioides difficile</i> strain 630, which features an <i>N</i>-acetylglucosamine linked to an <i>N</i>-methylthreonine via a phosphodiester bond. This study aimed to characterize the b-type glycan structure in <i>Pseudomonas aeruginosa</i> PAO1 using a set of mass spectrometry experiments. For this purpose, we used wild-type <i>P. aeruginosa</i> PAO1 and several gene mutants from the b-type glycan biosynthetic cluster. Moreover, we compared the mass spectrometry characteristics of the b-type glycan with those of <i>in vitro</i> modified Type A-peptides from <i>C. difficile</i> strain 630Δ<i>erm</i>. Our results demonstrate that the thus far unknown moiety of the b-type glycan in <i>P. aeruginosa</i> consists of an <i>N,N</i>-dimethylthreonine. These data allowed us to refine our model of the flagellin glycan biosynthetic pathway in both <i>P. aeruginosa</i> PAO1 and <i>C. difficile</i> strain 630.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":"518-528"},"PeriodicalIF":4.0000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833859/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.4c00896","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Flagella are essential for motility and pathogenicity in many bacteria. The main component of the flagellar filament, flagellin (FliC), often undergoes post-translational modifications, with glycosylation being a common occurrence. In Pseudomonas aeruginosa PAO1, the b-type flagellin is O-glycosylated with a structure that includes a deoxyhexose, a phospho-group, and a previous unknown moiety. This structure resembles the well-characterized glycan (Type A) in Clostridioides difficile strain 630, which features an N-acetylglucosamine linked to an N-methylthreonine via a phosphodiester bond. This study aimed to characterize the b-type glycan structure in Pseudomonas aeruginosa PAO1 using a set of mass spectrometry experiments. For this purpose, we used wild-type P. aeruginosa PAO1 and several gene mutants from the b-type glycan biosynthetic cluster. Moreover, we compared the mass spectrometry characteristics of the b-type glycan with those of in vitro modified Type A-peptides from C. difficile strain 630Δerm. Our results demonstrate that the thus far unknown moiety of the b-type glycan in P. aeruginosa consists of an N,N-dimethylthreonine. These data allowed us to refine our model of the flagellin glycan biosynthetic pathway in both P. aeruginosa PAO1 and C. difficile strain 630.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.